Business Description
Ultragenyx Pharmaceutical Inc
NAICS : 325412
SIC : 2834
ISIN : US90400D1081
Description
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 18.24 | |||||
| Equity-to-Asset | 0.23 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.73 | |||||
| Beneish M-Score | -2.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.9 | |||||
| 3-Year EBITDA Growth Rate | -45.1 | |||||
| 3-Year EPS without NRI Growth Rate | -17.3 | |||||
| 3-Year FCF Growth Rate | -34.8 | |||||
| 3-Year Book Growth Rate | -42.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 26.75 | |||||
| Future 3-5Y Total Revenue Growth Rate | 25.25 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.15 | |||||
| 9-Day RSI | 33.38 | |||||
| 14-Day RSI | 35.24 | |||||
| 6-1 Month Momentum % | 19.29 | |||||
| 12-1 Month Momentum % | -0.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.81 | |||||
| Quick Ratio | 2.65 | |||||
| Cash Ratio | 2.18 | |||||
| Days Inventory | 188.02 | |||||
| Days Sales Outstanding | 63.15 | |||||
| Days Payable | 215.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.2 | |||||
| Shareholder Yield % | -0.14 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.25 | |||||
| Operating Margin % | -102.49 | |||||
| Net Margin % | -106.93 | |||||
| FCF Margin % | -84.08 | |||||
| ROE % | -227.85 | |||||
| ROA % | -38.86 | |||||
| ROIC % | -69.78 | |||||
| ROC (Joel Greenblatt) % | -171.1 | |||||
| ROCE % | -42.38 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.31 | |||||
| PB Ratio | 11.67 | |||||
| Price-to-Tangible-Book | 29.44 | |||||
| EV-to-EBIT | -7.06 | |||||
| EV-to-Forward-EBIT | -6.73 | |||||
| EV-to-EBITDA | -7.59 | |||||
| EV-to-Forward-EBITDA | -6.8 | |||||
| EV-to-Revenue | 6.7 | |||||
| EV-to-Forward-Revenue | 5.19 | |||||
| EV-to-FCF | -7.97 | |||||
| Earnings Yield (Greenblatt) % | -14.16 | |||||
| FCF Yield % | -10.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RARE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ultragenyx Pharmaceutical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 522.745 | ||
| EPS (TTM) ($) | -6.47 | ||
| Beta | 0.07 | ||
| Volatility % | 45.75 | ||
| 14-Day RSI | 35.24 | ||
| 14-Day ATR ($) | 1.771698 | ||
| 20-Day SMA ($) | 46.6565 | ||
| 12-1 Month Momentum % | -0.55 | ||
| 52-Week Range ($) | 37.02 - 60.37 | ||
| Shares Outstanding (Mil) | 92.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ultragenyx Pharmaceutical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ultragenyx Pharmaceutical Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ultragenyx Pharmaceutical Inc Frequently Asked Questions
What is Ultragenyx Pharmaceutical Inc(RARE)'s stock price today?
The current price of RARE is $43.75. The 52 week high of RARE is $60.37 and 52 week low is $37.02.
When is next earnings date of Ultragenyx Pharmaceutical Inc(RARE)?
The next earnings date of Ultragenyx Pharmaceutical Inc(RARE) is 2025-02-14 Est..
Does Ultragenyx Pharmaceutical Inc(RARE) pay dividends? If so, how much?
Ultragenyx Pharmaceutical Inc(RARE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers